Current Understanding of Urachal Adenocarcinoma and Management Strategy
- 27 January 2020
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 22 (1) , 9
Abstract
The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians.Keywords
This publication has 61 references indexed in Scilit:
- Immunohistochemical Analysis in a Morphologic Spectrum of Urachal Epithelial NeoplasmsAmerican Journal of Surgical Pathology, 2011
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Predictors of survival from urachal cancerCancer, 2007
- Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancyCancer, 2006
- Complete response of a recurrent advanced urachal carcinoma treated by S‐1/cisplatin combination chemotherapyInternational Journal of Urology, 2006
- Uncommon Cancers of the Bladder2006
- Irinotecan as a New Agent for Urachal CancerUrologia Internationalis, 2006
- CARCINOMA OF THE URACHUSBritish Journal of Urology, 1971